In Stock, Ready to Ship!
Price range: $180.00 through $350.00 — or subscribe and save 20%
GLP-3 is a cutting-edge tri-agonist peptide that is transforming the field of metabolic research. Designed to simultaneously activate the GLP-1, GIP, and GCGR (glucagon) receptors, this multifunctional peptide offers a more comprehensive and synergistic approach to modulating appetite, enhancing insulin function, and accelerating fat metabolism.
Peptides are not ready to use. Must purchase BAC water for reconstitution.
In controlled laboratory studies, models administered retatrutide exhibited an average reduction equivalent to approximately 24% of baseline mass over a 48-week evaluation period. These findings are based on Phase-2 data and should be interpreted within the scope of scientific research only.
For research use only. Not for human or veterinary use.
Retatrutide is a tri-agonist peptide shown in laboratory studies to simultaneously activate GLP-1, GIP, and glucagon receptors. This unique combination has been observed to influence appetite signaling pathways and support energy regulation in research models.
For laboratory research use only. Not for human or animal use.
In controlled laboratory studies, Retatrutide has been observed to influence biomarkers such as HbA1c, fasting glucose levels, and insulin sensitivity in experimental models. These findings suggest potential metabolic modulation for further investigation.
For research use only. Not for human consumption or therapeutic application.
Research trials often employ a once-weekly subcutaneous micro-dosing approach, typically around 0.1 mL, to maintain consistent exposure levels in peptide models. This allows for sustained analysis without requiring daily administration.
For research use only. Not approved for human consumption or clinical use.
Research models receiving GLP-1 class peptides such as Retatrutide have shown mild and temporary gastrointestinal reactions, generally decreasing as dosage protocols are stabilized. These observations are consistent with GLP-1-related pathways in research.
Retatrutide is not intended for human or diagnostic use. For qualified research personnel only.
Retatrutide (Reta GLP-3) is a 39-amino-acid synthetic peptide engineered as a tri-agonist for the GLP-1, GIP, and glucagon receptors. By combining three receptor activities, Retatrutide provides a powerful tool to investigate multi-pathway metabolic control, including satiety, insulin secretion, and lipid breakdown—without needing separate agonists.
Researchers choose Retatrutide when they need a single-molecule solution for complex metabolic-health studies. Its tri-agonist design delivers synchronized receptor activation that mimics cutting-edge therapeutic candidates, enabling streamlined protocols for appetite-control assays, lipolysis and thermogenesis modeling, and energy-expenditure measurements. Manufactured under ISO-certified conditions and verified to ≥ 99% purity with low endotoxin, Retatrutide ensures consistent, high-fidelity data across in vitro and in vivo experiments.
Source: Jastreboff et al., New England Journal of Medicine, 2023
Source: Killion et al., Nature Metabolism, 2022
Source: U.S. Food & Drug Administration, 2023
Source: Hall et al., Endocrinology Today, 2022
Retatrutide is a research-grade peptide known for its tri-agonist activity—activating GLP-1, GIP, and glucagon receptors simultaneously. It is being studied in scientific settings for its unique mechanism of action across metabolic pathways.
No. Retatrutide is a synthetic peptide, engineered in laboratory settings to mimic and enhance the function of naturally occurring hormonal pathways in research models.
Retatrutide is commonly studied in metabolic, obesity, glucose regulation, and energy balance models. Its triple-receptor profile makes it an ideal candidate for preclinical exploration of multi-receptor metabolic interactions.
Research protocols often begin with 0.25mg and may scale to 0.5mg or 1mg, depending on the experimental model and study goals. Dosage should be determined based on internal SOPs and protocol requirements.
Yes. Dosage charts for Retatrutide are typically created based on model weight, study length, and receptor activation goals. Charts often show titration schedules from 0.25mg up to 1mg over several weeks.
Yes. Retatrutide is frequently used in research stacks with peptides such as Tesamorelin, CJC-1295, or Cagrilintide to explore synergistic effects in metabolic modeling.
No. Retatrutide is classified as a triple agonist, meaning it activates GLP-1, GIP, and GCGR receptors, offering a broader biological profile for researchers studying complex peptide interactions.
Lyophilized Retatrutide should be stored at or below -20°C for long-term stability. After reconstitution, storage in a refrigerated environment is generally recommended as per research protocols.
No. Retatrutide is not approved by the FDA and is sold strictly for laboratory and research purposes only. It is not intended for human or veterinary use.
Our Retatrutide is USA-manufactured under cGMP-like conditions, with each batch lab-tested for purity, potency, and consistency. Certificates of Analysis (COA) are provided for all research peptides.
Don't hestitate to contact us
End of Content.
